Guinness Atkinson Asset Management Inc Buys 1,234 Shares of Danaher Co. (NYSE:DHR)

Guinness Atkinson Asset Management Inc grew its stake in Danaher Co. (NYSE:DHR) by 4.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 26,611 shares of the conglomerate’s stock after purchasing an additional 1,234 shares during the period. Danaher makes up about 3.1% of Guinness Atkinson Asset Management Inc’s portfolio, making the stock its 17th biggest position. Guinness Atkinson Asset Management Inc’s holdings in Danaher were worth $6,109,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Decker Retirement Planning Inc. bought a new stake in Danaher in the fourth quarter worth $31,000. Teachers Insurance & Annuity Association of America purchased a new stake in shares of Danaher in the third quarter valued at $39,000. MidAtlantic Capital Management Inc. bought a new stake in shares of Danaher in the 3rd quarter worth about $40,000. FSA Wealth Management LLC purchased a new position in shares of Danaher during the 3rd quarter worth about $50,000. Finally, Darwin Wealth Management LLC bought a new position in Danaher during the 3rd quarter valued at about $55,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

NYSE DHR opened at $238.41 on Monday. The firm’s fifty day simple moving average is $234.85 and its two-hundred day simple moving average is $253.42. The firm has a market capitalization of $172.20 billion, a P/E ratio of 45.50, a P/E/G ratio of 4.23 and a beta of 0.83. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. Danaher Co. has a 12-month low of $222.53 and a 12-month high of $281.70.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the previous year, the business earned $2.02 EPS. The firm’s revenue for the quarter was up 3.1% on a year-over-year basis. Analysts forecast that Danaher Co. will post 7.49 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. The ex-dividend date is Friday, December 27th. Danaher’s dividend payout ratio (DPR) is presently 20.61%.

Analysts Set New Price Targets

DHR has been the subject of several analyst reports. Barclays decreased their price objective on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 23rd. Citigroup dropped their price objective on Danaher from $305.00 to $285.00 and set a “buy” rating for the company in a report on Monday, January 6th. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. TD Cowen lifted their target price on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research report on Wednesday, October 23rd. Finally, KeyCorp upped their price target on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. Six research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $286.80.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.